(IN BRIEF) Sanofi has agreed to acquire UK-based Vicebio for $1.15 billion upfront plus up to $450 million in milestones, with closing anticipated in Q4 2025. The deal adds an early-stage bivalent RSV/hMPV vaccine (VXB‑241, in Phase 1 for older adults) and … Read the full press release →
Posted in Artificial Intelligence (AI), Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acquisition, AI-powered biopharma, Daniel Watterson, Emmanuel Hanon, fully liquid combination vaccines, Jean-François Toussaint, Keith Chappell, lower respiratory tract infections, Medicxi, Molecular Clamp technology, non-mRNA vaccine, Older Adults, partnership, Paul Young, pneumonia, prefilled syringes, regulatory approvals, respiratory vaccines pipeline, seasonal surges, Tags: Sanofi, UniQuest, University of Queensland, Vicebio